MX2022011240A - Azálidos de urea inmunomoduladores. - Google Patents

Azálidos de urea inmunomoduladores.

Info

Publication number
MX2022011240A
MX2022011240A MX2022011240A MX2022011240A MX2022011240A MX 2022011240 A MX2022011240 A MX 2022011240A MX 2022011240 A MX2022011240 A MX 2022011240A MX 2022011240 A MX2022011240 A MX 2022011240A MX 2022011240 A MX2022011240 A MX 2022011240A
Authority
MX
Mexico
Prior art keywords
sup
immunomodulating
formula
azalides
urea
Prior art date
Application number
MX2022011240A
Other languages
English (en)
Inventor
Graham M Kyne
Paul D Johnson
Rajendran Vairagoundar
Richard Andrew Ewin
Mark R Cox
Timothy L Stuk
Todd M Maddux
Tomasz Respondek
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of MX2022011240A publication Critical patent/MX2022011240A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Formula 1. En la presente se definen compuestos inmunomoduladores de Fórmula (1) en donde R, R0, R1, R2, R3 y W son tal como se define en la presente, estereoisómeros de estos y sales farmacéuticamente aceptables de estos; y composiciones que comprenden dichos compuestos. La invención también incluye métodos para tratar una enfermedad o trastorno inflamatorio y/o inmunológico en un animal al administrar una cantidad terapéuticamente efectiva de un compuesto 10 de la Fórmula (1), estereoisómero de este y una sal farmacéuticamente aceptable de este; o uso de dicho compuesto de Fórmula (1) para preparar un medicamento para tratar una enfermedad o trastorno inflamatorio y/o inmunológico en un animal.
MX2022011240A 2020-03-12 2021-03-11 Azálidos de urea inmunomoduladores. MX2022011240A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062988492P 2020-03-12 2020-03-12
PCT/US2021/021897 WO2021183758A1 (en) 2020-03-12 2021-03-11 Immunomodulating urea azalides

Publications (1)

Publication Number Publication Date
MX2022011240A true MX2022011240A (es) 2022-12-15

Family

ID=75278424

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022011242A MX2022011242A (es) 2020-03-12 2021-03-11 Inmunomodulación de o-het/aril azálidos.
MX2022011240A MX2022011240A (es) 2020-03-12 2021-03-11 Azálidos de urea inmunomoduladores.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2022011242A MX2022011242A (es) 2020-03-12 2021-03-11 Inmunomodulación de o-het/aril azálidos.

Country Status (13)

Country Link
US (5) US11771677B2 (es)
EP (2) EP4118092A1 (es)
JP (2) JP2023517673A (es)
KR (1) KR20220156570A (es)
CN (2) CN115461353A (es)
AR (1) AR121554A1 (es)
AU (2) AU2021232959B2 (es)
BR (2) BR112022017779A2 (es)
CA (2) CA3175087A1 (es)
MX (2) MX2022011242A (es)
TW (1) TWI830987B (es)
WO (4) WO2021183754A1 (es)
ZA (1) ZA202209530B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023038852A1 (en) 2021-09-07 2023-03-16 Zoetis Services Llc Immunomodulating azalides

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60003586T2 (de) * 2000-01-27 2004-01-08 Pfizer Products Inc., Groton Antibiotische azalid-zusammensetzungen
ITMI20040124A1 (it) * 2004-01-29 2004-04-29 Zambon Spa Macrolidi ad attivita' antiinfiammatoria
WO2007129646A1 (ja) 2006-05-01 2007-11-15 Taisho Pharmaceutical Co., Ltd. マクロライド誘導体
JP2010535776A (ja) 2007-08-10 2010-11-25 ワイズセラピューティックス株式会社 ロキシスロマイシン又はその誘導体の投与による免疫応答の調節
EP2271656A1 (en) * 2008-04-23 2011-01-12 Glaxo Group Limited 2'-o,3'-n-bridged macrolides
US20130045939A1 (en) 2010-03-19 2013-02-21 Catabasis Pharmaceuticals, Inc. Fatty acid macrolide derivatives and their uses
WO2013148874A1 (en) * 2012-03-27 2013-10-03 Burnet Michael W Anti-inflammatory macrolides
CA2908620A1 (en) 2013-04-10 2014-10-16 Probiotic Pharmaceuticals Aps Azithromycin antimicrobial derivatives with non-antibiotic pharmaceutical effect
GB201608236D0 (en) * 2016-05-11 2016-06-22 Fidelta D O O Seco macrolide compounds

Also Published As

Publication number Publication date
AU2021232959A1 (en) 2022-09-15
JP2023517674A (ja) 2023-04-26
WO2021183758A1 (en) 2021-09-16
CN115461353A (zh) 2022-12-09
US11771677B2 (en) 2023-10-03
AU2021233895A1 (en) 2022-09-29
TW202200158A (zh) 2022-01-01
MX2022011242A (es) 2022-12-15
TWI830987B (zh) 2024-02-01
JP2023517673A (ja) 2023-04-26
US20230136177A1 (en) 2023-05-04
EP4118092A1 (en) 2023-01-18
CN115461352A (zh) 2022-12-09
US20230390237A1 (en) 2023-12-07
US20230137567A1 (en) 2023-05-04
AR121554A1 (es) 2022-06-15
WO2021183762A1 (en) 2021-09-16
WO2021183754A1 (en) 2021-09-16
CA3175087A1 (en) 2021-09-16
US20210290591A1 (en) 2021-09-23
WO2021183759A1 (en) 2021-09-16
US20230129438A1 (en) 2023-04-27
AU2021232959B2 (en) 2023-09-07
EP4118091A1 (en) 2023-01-18
BR112022017015A2 (pt) 2022-11-16
BR112022017779A2 (pt) 2022-11-29
ZA202209530B (en) 2024-02-28
KR20220156570A (ko) 2022-11-25
CA3175114A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
MX2023000798A (es) Peptidos funcionalizados como agentes antivirales.
MX2021013472A (es) Moduladores de thr-? y metodos de uso de estos.
CR20230310A (es) Inhibidores de prmt5
BR0314126A (pt) Ligandos de amida acìclica e sulfonamida para o receptor de estrogênio
WO2017123884A8 (en) Heterocyclic compounds as rsv inhibitors
EP4306523A3 (en) Imidazoquinoline compounds and uses thereof
MX2022010011A (es) Inhibidores de prmt5 novedosos.
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
EA200501098A1 (ru) Антибактериальные агенты
MX2010007375A (es) Nuevos derivados de lupano.
MX2023005984A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
RU2013108857A (ru) Соединения для лечения/профилактики воспалительных глазных заболевний
MX2010007374A (es) Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos.
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
MX2021011606A (es) Compuestos dirigidos a prmt5.
MX2023001756A (es) Peptidos funcionalizados como agentes antivirales.
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
MX2022012812A (es) Métodos para tratar el síndrome de liberación de citocinas.
MX2020002429A (es) Compuestos para reducir la viscosidad de las formulaciones biologicas.
MX2021011144A (es) Derivados de las benzodiazepinas como inhibidores del vsr.
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
MX2022011240A (es) Azálidos de urea inmunomoduladores.
MX2023000943A (es) Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y metodos de uso de los mismos.